Ajanta Pharma

Ajanta Pharma Limited
Public Company
Traded as
Industry Pharmaceuticals, Drugs & Healthcare
Founded 1973
Headquarters Mumbai, Maharashtra[1], India
Key people

Yogesh Agrawal, Managing Director.

Rajesh Agrawal, Joint Managing Director
Products Branded Generic Formulations / Medicines
Revenue Increase ₹1453 crore (US$220 million) (2014–2015)
Number of employees
 6000+
Subsidiaries

Ajanta Pharma (Mauritius) Ltd, Ajanta Pharma Philippines Inc., Ajanta Pharma USA Inc.,

Ajanta Pharma Nigeria Ltd.[2]
Website Official Website

Ajanta Pharma Limited (APL) (BSE: 532331 | NSE: AJANTPHARM) is an Indian multinational, engaged in development, manufacture and marketing of pharmaceutical formulations worldwide, with its headquarters in Mumbai. It has a robust business of Branded Generics across India and about 35 emerging markets. The company has presence in fast-growing specialty therapeutic segments of Cardiology, Dermatology, Ophthalmology and Pain management apart from serving many other main line therapeutic segments like Anti-malarial, Premium anti-biotic, Anti-allergy etc. With its mission of 'Serving Global Health Care Needs Worldwide', a team of 6000+ Ajantaites with different nationalities ensure providing quality medicines to the patients in different parts of the world. Established in 1973, Ajanta Pharma has rich experience of over 4 decades in pharma industry with impeccable record of quality. The company has always been pioneering in its efforts to service the ailing mankind. It has unique advantage of launching innovative R&D products in the market ahead of competition, many of them being first of its kind.

Domestic Business

In India, APL has presence in the fast-growing specialty therapeutic segments of Cardiology, Dermatology, Ophthalmology and Pain management and has been consistently improving its ranking over the years. Company has been launching many new products for providing patient compliance and convenience, which is enabling it to enjoy superior ranking in its therapeutic segments and leadership in some of the sub-therapeutic segments it operates in. Currently company has a basket of 190+ products, out of which 130 are first-to-market in India. A dedicated team of 3000+ field force spread across the country services the domestic market.

Global Business

Ajanta has built an outstanding brand image in the emerging markets of Asia and Africa and is in the process of establishing its presence in USA, the largest pharmaceutical market globally. Ajanta’s export business consists of a basket of 200+ products, which are customized to suit the requirement of each country to make it a specialty business in each of the markets. Currently company’s products are available in more than 35 countries and in many of the markets company’s products are among the leaders in the segment.Currently, Ajanta has 1400+ product registrations in hand and another 1700+ are waiting for approval in various countries which ensures continued growth in coming years.

APL currently has 7 ANDAs (Abbreviated New Drug Application) which are either commercialized or in process of being commercialized. 2 more ANDA's have received tentative approval and we have 17 ANDA's under approval with US FDA. Company plans to file 8-12 ANDAs every year with an objective of strengthening its presence in the US market. APL also has been granted marketing authorization (MA) for Sildenafil Citrate Tablets 50mg & 100mg in UK, Germany, France, The Netherlands, Denmark, Ireland, Hungary, Portugal and Bulgaria and awaiting the MA in Italy, Greece and Belgium which is expected shortly.

Manufacturing Facilities

Ajanta Pharma operates 6 state-of-the-art manufacturing facilities; 5 within India and 1 in Mauritius. In India, 4 facilities manufacture finished formulations and 1 manufactures Active Pharmaceutical Ingredients (APIs) primarily for captive consumption. To this list the recent addition is the facility for Regulated markets which has come up at Dahej, Gujarat. The facility has started taking regulatory filing batches.

The company is in the process of setting up 1 more formulations manufacturing facility at Guwahati in Assam for domestic and emerging markets and is in the process of finalising its plans. Addition of these facilities will ensure adequate capacities to cater to Company's growth in coming years.

R&D

APL has in-house R&D centre recognized by DSIR, Govt. of India, which has state-of-the-art facilities for product and process development

References

  1. ↑ "Welcome To Ajanta Pharma". Ajantapharma.com. Retrieved 29 February 2016.
  2. ↑ "Ajanta Pharma Limited - Our Business". Company. Retrieved 29 February 2016.

External links

This article is issued from Wikipedia - version of the Saturday, April 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.